New government price setting policy threatens post-approval research
Have you ever noticed that one medicine might be used to treat two, three, seven different conditions? That ’s the result of significant additional research and investment, including lengthy and costly clinical trials, biopharmaceutical companies undertake after a medicine is initially approved by the Food and Drug Administration (FDA). Suchpost approval R&D has changed the course of treatment for many diseases and patient populations. Despite this, the recently enacted Inflation Reduction Act disincentivizes post-approval R&D, and asa new analysis demonstrates, this is very concerning for patients across the cou...
Source: The Catalyst - November 10, 2022 Category: Pharmaceuticals Tags: Research and Development Government Price Setting Source Type: news
Congratulations to our 2022 Working for Cures Employee Champions
The Working for Cures Employee Champion Awards celebrate the real people in our industry who go above and beyond to advance science and support the work our industry does for patients. (Source: The Catalyst)
Source: The Catalyst - November 10, 2022 Category: Pharmaceuticals Tags: Research and Development PhRMA Member Company Source Type: news
Expanding the WTO intellectual property waiver will hurt American jobs
The June decision by WTO members to waive commitments to protect intellectual property (IP) for COVID-19 vaccines under the Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement was a political and ineffective measure thatdoes not address the true barriers to vaccine equity. Now, some are pushing to extend this harmful waiver to COVID-19 treatments, even though production exceeds demand for treatments, including for the most effective antivirals and monoclonal antibodies. Allowing foreign governments and competitors to disregard IP protections will result in a loss of American jobs and hamper much-needed ...
Source: The Catalyst - November 9, 2022 Category: Pharmaceuticals Authors: Megan Van Etten Tags: Intellectual Property Coronavirus TRIPS Waiver Source Type: news
ICYMI: PhRMA COO Lori Reilly Esq. speaks with Jacob Van Naarden about the future of cancer research
Our health care ecosystem has made tremendous progress in the fight against cancer, with the cancer death rate falling 32% from its peak in 1991. On November 3, PhRMA sponsored The Atlantic ’s People v. Cancer event, hosting the sessionPhRMA Presents: The Future of Fighting Cancer. PhRMA ’s COO Lori Reilly, Esq., spoke with Eli Lilly and Company’s Jacob Van Naarden, CEO of Loxo@Lilly, about the incredible advancements made in cancer treatment. (Source: The Catalyst)
Source: The Catalyst - November 8, 2022 Category: Pharmaceuticals Authors: Emilie Signora Tags: Research and Development Cancer Source Type: news
Traditional HTA methods treat everyone like the “average” patient
Concerns about the cost of health care have led to calls for the use of health technology assessments or HTAs by the federal government. This would allow government agencies to make important decisions about patient access to health care based on their determination of the value of new tests and treatments. It ’s important to consider the best available information and evidence when making health care decisions. However, traditional HTA models often rely on flawed approaches that ignore patient differences and reinforce health disparities, which can ultimately lead to limited access to lifesaving treatm ents. (Source: The Catalyst)
Source: The Catalyst - November 7, 2022 Category: Pharmaceuticals Authors: Katie Koziara Tags: Value Assessment Health Equity Source Type: news
New paper: Addressing the growing crisis of mental health and substance use disorders
The United States is facing a crisis of mental health and addiction that has left few Americans and families unimpacted by these illnesses and the devastating consequences that are often associated with them. Mental illness refers to a wide range of mental health conditions that can affect mood, thinking and behavior. These illnesses include substance use disorders and such conditions as depression, anxiety disorders, schizophrenia, bipolar disorder and eating disorders. (Source: The Catalyst)
Source: The Catalyst - November 7, 2022 Category: Pharmaceuticals Authors: Lindsey Seidlitz Tags: Research and Development Mental Health Source Type: news
PhRMA submission to USTR calls for urgent defense of American innovation abroad
The United States leads the world in medicine research, development and manufacturing, and international trade delivers those medicines to patients around the globe. But trade barriers imposed in many countries impede the ability of U.S. biopharmaceutical companies to export even more American-made medicines and employ even more scientists, researchers and factory workers. (Source: The Catalyst)
Source: The Catalyst - November 1, 2022 Category: Pharmaceuticals Authors: Douglas Petersen Tags: Intellectual Property Trade TRIPS Waiver Source Type: news
Protecting treatment advances for National Breast Cancer Awareness Month
Since the 1980s, October has been recognized as National Breast Cancer Awareness Month — an opportunity for us to unite as a community to honor those who have had breast cancer and raise awareness about progress biopharmaceutical researchers have made towards treating the disease. (Source: The Catalyst)
Source: The Catalyst - October 31, 2022 Category: Pharmaceuticals Authors: Jocelyn Ulrich Tags: Research and Development Cancer Source Type: news
Protecting treatment advances for breast cancer
Since the 1980s, October has been recognized as National Breast Cancer Awareness Month — an opportunity for us to unite as a community to honor those who have had breast cancer and raise awareness about progress biopharmaceutical researchers have made towards treating the disease. (Source: The Catalyst)
Source: The Catalyst - October 31, 2022 Category: Pharmaceuticals Authors: Jocelyn Ulrich Tags: Research and Development Cancer Source Type: news
Identifying and addressing health disparities: PhRMA's first chart pack on health equity
PhRMA is proud to announce the release of its first everchart pack on health equity. This chart pack contains information on health equity in three sections: (1) A Snapshot of Health Disparities in America, (2) Inequities in Access to Screenings and Medicines Allow Health Disparities to Persist, and (3) PhRMA ’s Commitment to Building a More Equitable Health Care System for All. As a public health professional, health equity is a cornerstone of the work I do as it impacts every aspect of our nation’s health care system. Unfortunately, some populations face unequitable access to care due to their back ground, where they...
Source: The Catalyst - October 27, 2022 Category: Pharmaceuticals Authors: Kristin Williams Tags: Equity Source Type: news
In their own words: Insured Americans struggle to navigate complex coverage
A survey of more than 5,000 Americans conducted with Ipsos found that nearly 40% of insured Americans struggle to understand what their health insurance covers. (Source: The Catalyst)
Source: The Catalyst - October 26, 2022 Category: Pharmaceuticals Authors: Tom Wilbur Tags: Health Insurance Out-of-Pocket Costs Pharmacy Benefit Managers Polling Source Type: news
The law driving technology transfer and fostering innovation
The bipartisan Bayh-Dole Act created a framework for researchers receiving federal funds to patent and license their inventions to companies for further development and commercialization. This benefits innovators across many sectors. (Source: The Catalyst)
Source: The Catalyst - October 24, 2022 Category: Pharmaceuticals Authors: Megan Van Etten Tags: Research and Development Intellectual Property Source Type: news
Three ways 340B is failing vulnerable patients
The 340B Drug Pricing Program is 30 years old this year, but asThe New York Timesrecently spelled out, the program has become a profit engine for large health systems over the years instead of a program that helps vulnerable, low-income patients. Powerful hospitals have twisted the program to boost their bottom line. (Source: The Catalyst)
Source: The Catalyst - October 20, 2022 Category: Pharmaceuticals Tags: 340B Source Type: news
Word of the Month: What is Long COVID?
What is Long COVID? (Source: The Catalyst)
Source: The Catalyst - October 19, 2022 Category: Pharmaceuticals Authors: Mike Ybarra Tags: Vaccines Coronavirus Source Type: news
Word of the Month: Long COVID
What is Long COVID? (Source: The Catalyst)
Source: The Catalyst - October 19, 2022 Category: Pharmaceuticals Authors: Mike Ybarra Tags: Vaccines Coronavirus Word of the Month Source Type: news
